Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Abstract Background Chronic myeloid leukemia (CML) remains a therapeutic challenge, particularly in patients who develop resistance to standard tyrosine kinase inhibitors (TKIs) such as imatinib. Here, we present the first demonstration of the potent anti-leukemic activity of the histone deacetylase...

Full description

Saved in:
Bibliographic Details
Main Authors: Haeun Yang, Vladimir Li, Su Jung Park, Sang Won Cheon, Anne Lorant, Aloran Mazumder, Jin Young Lee, Barbora Orlikova-Boyer, Claudia Cerella, Christo Christov, Gilbert Kirsch, Dag Erlend Olberg, Guy Bormans, Hyoung Jin Kang, Byung Woo Han, Michael Schnekenburger, Marc Diederich
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Clinical Epigenetics
Subjects:
Chronic myeloid leukemia
HDAC inhibitors
Imatinib resistance
Cell death
Combination treatment
Online Access:https://doi.org/10.1186/s13148-025-01921-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items